Information Provided By:
Fly News Breaks for May 8, 2015
VRTX
May 8, 2015 | 14:13 EDT
Evercore ISI said it believes the FDA is still likely to grant approval for Vertex's Orkambi drug for CF, but the firm thinks the questions raised in the panel briefing documents may make reimbursement talks outside the U.S. more difficult for the company. Evercore maintains its Hold rating and $130 price target on Vertex.
News For VRTX From the Last 2 Days
There are no results for your query VRTX